NRCx-201
Our two oral ketamine products:
- NRCx-201-IR is our immediate release capsule formulation.
- NRCx-201-AD is our abuse deterrent formulation.
Oral NRCx-201 is an immediate release, abuse-deterrent, capsule formulation of therapeutic ketamine for the treatment of various mood disorders such as Treatment Resistant Depression (TRD) and bipolar depressions.
NRCx-201 has completed a Phase1 human trial which demonstrated the agent is safe and well tolerated at multiple dose levels where active drug concentrations and clinical activity are also observed.
We are now commencing additional trials – one for the treatment of bipolar depression, and additional studies in patients with other types of depression where the medicine is clinically indicated.
NRCx-201-AD is intended to be the first standard prescription form of ketamine available for use as a routine and cost-effective oral medication to treat depression.
Benefits.
Immediate Release
NRCx-201 (Keticap®) is an immediate release treatment, intended to benefit the patient within 50-60 minutes of the capsule being taken orally. This applies to our powder-filled capsule and the abuse-deterrent variation.
Abuse Deterrent
NRCx-201 (Keticap®) abuse-deterrent capsules contain a gel-like substance in which the ketamine is dissolved. This means the drug cannot be manipulated for abusive purposes such as snorting or injecting. The formulation is designed for immediate release, with drug release and absorption into the body within 60 minutes of administration.
Evidence of effects
Our Phase1 study demonstrated Keticap is delivering sufficient levels of ketamine and its major metabolites to have Pharmacodynamic effects. The findings will be confirmed in the upcoming Phase II/III trials in patients.
Clinical Indications.
Depression
Depression is a common but serious condition that affects how a person feels, thinks, and goes about their daily life. It can cause long-lasting sadness, low energy, trouble sleeping or eating, and difficulty concentrating or enjoying things. Also known as major depression or clinical depression, it affects about 1 in 6 adults and often gets in the way of work, relationships, and overall wellbeing. While many people improve with standard treatments, some find little relief after repeated attempts— this is known as treatment-resistant depression.
Bipolar Depression
Bipolar depression is a phase of bipolar disorder where someone experiences deep lows, similar to major depression. These episodes can include sadness, fatigue, and loss of interest, making it hard to function day to day. What makes bipolar disorder unique is that these lows may be followed by periods of high energy or mania. Many people with bipolar depression struggle to find effective treatments, as options are limited and responses can vary.
Abuse Deterrent.
Strong Patents.
Phase 2 Trials Underway.
Multiple Disease Indications.
Investors & Partners
Patients & Healthcare Professionals
Investors & Partners
Patients & Healthcare Professionals
